CTI BioPharma Investor
CTI BioPharma is a company that focuses on developing and selling cancer treatment products. One of its main products in development is Pixantrone, which is currently in phase III trials and is intended for non-Hodgkin's lymphoma.
Founded Date:
1991
Headquarters:
Seattle, Washington, United States
Employee Number:
11-50
Industry:
Biotechnology
Estimated Revenue:
$1M to $10M
Funding Status:
IPO
Investor Type:
For Profit